Mechanisms ot Maternal Immune Tolerence
母体免疫耐受机制
基本信息
- 批准号:6741858
- 负责人:
- 金额:$ 40.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-08-01 至 2007-05-31
- 项目状态:已结题
- 来源:
- 关键词:antigen presenting cellcytotoxic T lymphocytedendritic cellsgenetically modified animalshelper T lymphocytehormone regulation /control mechanismimmune tolerance /unresponsivenesslaboratory mouseleukocyte activation /transformationovalbuminplacentapregnancy immunologytissue /cell culturetrophoblastuterus
项目摘要
Description (provided by applicant): How the allogeneic fetus avoids maternal
immune rejection during pregnancy is not only one of the outstanding questions
in contemporary immunology, but is also now recognized to have major clinical
relevance towards diseases such as recurrent spontaneous abortion and
preeclampsia, as well as application towards organ transplantation. Although
it is generally accepted that the maternal immune system is ?aware? that the
fetus and placenta exist, studies to date have only focused on CD8+ T cells
and B cells, and thus have not addressed the behavior of potentially reactive
CD4+ T helper cells, the lymphocyte subset likely to play the most important
role in any form of antigen-specific tolerance induction. Here, we will
directly characterize the responses of both maternal CD4+ and CD8+ T cells
towards a placentally expressed antigen, taking advantage of transgenic mice
we have recently made that express the well-characterized model antigen
ovalbumin in placental tissues (Aim 1). The use of this system will also allow
us to test whether maternal tolerance towards the fetus and placenta is local
or systemic, and whether it involves attenuation of affector or effector arms
of the immune response. The nature of antigen presenting cells (APCs) in the
pregnant uterus is another area that is virtually unexplored, despite the
central role of these cells in regulating tolerance induction. Thus, we will
characterize the behavior and antigen-presenting capacity of APCs in the
pregnant uterus, focusing on resident dendritic cells, which have been
completely uncharacterized in mice (Aim 2). Lastly, we describe the generation
of novel transformed murine trophoblast cell lines directly from cultured
trophoblast stem cells. Since these transformed trophoblasts are rejected in
non-pregnant allogeneic mice following subcutaneous injection, they provide a
powerful reagent for dissecting the relative importance of trophoblasts, the
uterine environment, and the hormonal state of pregnancy in establishing
maternal tolerance (Aim 3).
描述(由申请人提供):异体胎儿如何避免母体
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAURIE Hollis GLIMCHER其他文献
LAURIE Hollis GLIMCHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LAURIE Hollis GLIMCHER', 18)}}的其他基金
Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer
制定实施社会风险转诊的实用指南:关爱健康中心 (CHC) 与癌症实施科学中心之间的合作伙伴关系
- 批准号:
10822141 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Understanding the impact of an EHR-integrated hereditary cancer risk assessment application on patient-provider communication
了解 EHR 集成遗传性癌症风险评估应用程序对患者与提供者沟通的影响
- 批准号:
10831167 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Real-World Molecularly Targeted Treatment Registry (MaTTeR): a Pilot Study to Enrich CCDI Data Utilizing Directed Electronic Medical Record (EMR) Extraction
真实世界分子靶向治疗登记处 (MaTTeR):利用定向电子病历 (EMR) 提取丰富 CCDI 数据的试点研究
- 批准号:
10878384 - 财政年份:2023
- 资助金额:
$ 40.5万 - 项目类别:
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
重新利用布鲁顿酪氨酸激酶 (BTK) 抑制剂来逆转高级别浆液性卵巢癌 (HGSC) 的免疫抑制
- 批准号:
10661823 - 财政年份:2022
- 资助金额:
$ 40.5万 - 项目类别:
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
重新利用布鲁顿酪氨酸激酶 (BTK) 抑制剂来逆转高级别浆液性卵巢癌 (HGSC) 的免疫抑制
- 批准号:
10512441 - 财政年份:2022
- 资助金额:
$ 40.5万 - 项目类别:
Multi-faceted Roles of an Atypical Kinase RIOK2 in Erythropoiesis and Myelodyplastic Syndromes
非典型激酶 RIOK2 在红细胞生成和骨髓增生异常综合征中的多方面作用
- 批准号:
10046930 - 财政年份:2020
- 资助金额:
$ 40.5万 - 项目类别:
Schnurri-3 Inhibitors: specific inducers of adult bone formation
Schnurri-3 抑制剂:成人骨形成的特异性诱导剂
- 批准号:
8259713 - 财政年份:2011
- 资助金额:
$ 40.5万 - 项目类别:
Schnurri-3 Inhibitors: specific inducers of adult bone formation
Schnurri-3 抑制剂:成人骨形成的特异性诱导剂
- 批准号:
8139368 - 财政年份:2011
- 资助金额:
$ 40.5万 - 项目类别:
相似海外基金
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 40.5万 - 项目类别:
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 40.5万 - 项目类别:
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 40.5万 - 项目类别:
Operating Grants
Utilizing intranasal immunization to induce a cytotoxic T lymphocyte response and reduce metastatic burden in the lung
利用鼻内免疫诱导细胞毒性 T 淋巴细胞反应并减少肺转移负担
- 批准号:
10090666 - 财政年份:2020
- 资助金额:
$ 40.5万 - 项目类别:
Re-sensitization of immune checkpoint therapy resistant cancers to cytotoxic T-lymphocyte mediated killing
免疫检查点疗法耐药性癌症对细胞毒性 T 淋巴细胞介导的杀伤重新敏感
- 批准号:
412967 - 财政年份:2019
- 资助金额:
$ 40.5万 - 项目类别:
Fellowship Programs
Mechanism for control of HIV-1 by cytotoxic T lymphocyte
细胞毒性T淋巴细胞控制HIV-1的机制
- 批准号:
17K10021 - 财政年份:2017
- 资助金额:
$ 40.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding the regulation of cytotoxic T lymphocyte signalling and activity through single-cell genomics
通过单细胞基因组学了解细胞毒性 T 淋巴细胞信号传导和活性的调节
- 批准号:
MR/P014178/1 - 财政年份:2017
- 资助金额:
$ 40.5万 - 项目类别:
Fellowship
Enhancing cytotoxic T lymphocyte (CTL) responses by directly loading CTL epitope vaccines onto MHC Class I complexes on the dendritic cell surface
通过将 CTL 表位疫苗直接负载到树突状细胞表面的 MHC I 类复合物上,增强细胞毒性 T 淋巴细胞 (CTL) 反应
- 批准号:
9299648 - 财政年份:2017
- 资助金额:
$ 40.5万 - 项目类别:
Discovery of Cytotoxic T Lymphocyte-inspired Bacteria Machine for Cancer Therapeutic Use Based on Synthetic Biological Approach
基于合成生物学方法发现细胞毒性 T 淋巴细胞启发的用于癌症治疗的细菌机器
- 批准号:
15K14415 - 财政年份:2015
- 资助金额:
$ 40.5万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Elucidation of molecular mechanism of SV40 VP1 capsid protein to induce aimed cytotoxic T lymphocyte against viruses and its application for vaccine formulation.
阐明SV40 VP1衣壳蛋白诱导针对病毒的细胞毒性T淋巴细胞的分子机制及其在疫苗制剂中的应用。
- 批准号:
26860112 - 财政年份:2014
- 资助金额:
$ 40.5万 - 项目类别:
Grant-in-Aid for Young Scientists (B)














{{item.name}}会员




